Open Beta
TREN
MetriLume
TREN

US marketsAMPH

SEC-sourced researchBeta

AMPH

Amphastar Pharmaceuticals, Inc.

Company comparison ↗

Data passport

CIK
0001297184
Exchange
Nasdaq
Business activity
Pharmaceutical Preparations · SIC 2834
Financial inputs
6/6
Filing date
Sep 23, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2023: 644,395,000.0000 USD; December 2024: 731,967,000.0000 USD; December 2025: 719,887,000.0000 USD732M USD0 USD0December 2023December 2024December 2025
AMPH · Exact amounts and source periods · USD
Period endRevenueFiling date
December 2023644,395,000.0000Feb 26, 2026
December 2024731,967,000.0000Feb 26, 2026
December 2025719,887,000.0000Feb 26, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 2025719,887,000.000098,094,000.0000156,115,000.00001,629,299,000.0000840,494,000.0000Feb 26, 2026
December 2024731,967,000.0000159,519,000.0000213,386,000.00001,577,470,000.0000845,172,000.0000Feb 26, 2026
December 2023644,395,000.0000137,545,000.0000183,503,000.0000——Feb 26, 2026

Explainable fundamental score

Five equally weighted components based on SEC financial inputs. No price inputs or personal investment preferences.

73/100
Profitability77
Growth48
Balance sheet48
Cash generation93
Data coverage100

Component weight: 20% · Minimum data coverage: 50% · Missing component value: 50/100

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenues$719.89MJan 1, 2025 – Dec 31, 2025Feb 26, 202610-K
Previous period revenueRevenues$731.97MJan 1, 2024 – Dec 31, 2024Feb 26, 202610-K
Net incomeNetIncomeLoss$98.09MJan 1, 2025 – Dec 31, 2025Feb 26, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities$156.12MJan 1, 2025 – Dec 31, 2025Feb 26, 202610-K
Total assetsAssets$1.63BDec 31, 2025Feb 26, 202610-K
Total liabilitiesLiabilities$840.49MDec 31, 2025Feb 26, 202610-K

New filings

Explore methodology ↗